Tomosynthesis Mammographic Imaging Screening Trial

Official Title

Tomosynthesis Mammography Imaging Screening Trial Lead-in


A randomized screening trial to compare the diagnostic accuracy of screening for breast cancer with three-dimensional digital breast tomosynthesis (DBT) plus two-dimensional full-field digital mammography (FFDM) versus FFDM alone.

Trial Description

Primary Outcome:

  • Diagnostic Accuracy of DBT vs FFDM - AUC under ROC comparison
Secondary Outcome:
  • Recall Rates
  • Interval Cancers
  • Prevalence of Breast Cancer Subtypes
  • Clinical Characteristics of Cancers
  • Reader Studies of variations of DBT vs FFDM - AUC under ROC comparison
  • Biomarker Correlation
The Tomosynthesis Mammography Imaging Screening Trial (TMIST) LEAD-IN is being conducted to ensure that all Eastern Cooperative Oncology Group / American College of Radiology Imaging Network (ECOG/ACRIN) TMIST components are properly functional and to provide an opportunity for fine tuning before launching the full TMIST. The accrual target for TMIST LEAD-IN is 6354 participants (one tenth of the projected enrollment target for TMIST) at three lead-in study sites: 1. Sunnybrook Health Sciences Centre in Toronto, 2. Vancouver (under the auspices of the Screening Mammography Programme of British Columbia) and 3. The Ottawa Hospital.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society